

24. Wilding, JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. *Metabolism* 2014;63:1228-1237.
25. Yakovleva T, Sokolov V, Chu L, et al. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: a quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. *Diabetes Obes Metab*. 2019; 21:2684-2693.
26. NCZI, štatistické výstupy 2023. [Internet]. Available from: https://www.nczisk.sk/Statisticke_vystupy/Tematicke_statisticke_vystupy/Diabetologia/Pages/default.aspx.
27. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358(24):2560-2572.
28. Galwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *Lancet*. 2012;380(9840):475-483.
29. Matthews DR, DeJager S, Ahren B, et al. Vildagliptin addition to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. *Diabetes Obes Metab*. 2010;12(9):780-789.
30. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. *Int J Clin Pract*. 2010;64(5):562-576.
31. Tkac I, Raz I. Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. *Diabetes Care*. 2017;40(2):284-286.
32. Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. *Diabetologia*. 2018;61(10):2098-2107.
33. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. *Annu Rev Med*. 2015;66:255-270.
34. Galajda P, Samoš M, Bolek T, et al. Desať rokov liečby pacientov s diabetes mellitus 2. typu gliflozínmi. *Forum Diabetologicum*. 2023;12(2):76-83.
35. Bosch A, Ott C, Jung S, et al. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. *Cardiovasc Diabetol*. 2019;18(1):44.
36. Covie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. *Nat Rev Cardiol*. 2020;17(12):761-772.
37. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A State-of-the-Art Review. *JACC Basic Transl Sci*. 2020;5(6):632-644.
38. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A „Thrifty Substrate” Hypothesis. *Diabetes Care*. 2016;39(7):1108-1114.
39. Sarwar N, Gao P, Kondapally Seshasai SR, et al. Emerging Risk Factors Collaboration; Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215-2222.
40. Lingvay I, Sumithran P, Cohen RV, et al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *Lancet*. 2022;399:394-405.
41. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. *Diabetes Care*. 2021;44:2438-2444.
42. Uličianský V, Schroner Z. Inhibitory sodíkového-glukózoového kotransportéru 2 (SGLT2) vs. Inhibitory dipeptidyl-peptidázy 4 (DPP4). *Súčasná klinická prax*. 2016;13(2):16-25.
43. Prázný M, Slíva J. Empagliflozin – nový zástupca inhibítora transportéru SGLT2 pro léčbu pacientů s diabetem 2. typu. *Vnitř Lék*. 2015;61(2):175-178.
44. Schroner Z. Inhibitor SGLT2 kanagliflozín: benefity v liečbe diabetes mellitus 2. typu. *Diabetes a obezita* 2023;23(45): 63-64.
45. Sánchez-García A, Simental-Mendía M, Millán-Alanís JM, et al. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. *Pharmacol Res*. 2020;160:105068.
46. Kern M, Klötting N, Mark M, et al. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. *Metabolism*. 2016;65(2):114-123.
47. Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, et al. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. *Expert Opinion on Drug Metabolism & Toxicology*. 2018;14(11):1113-1121.
48. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism. *Diabetes*. 2016;65(7):2032-2038.

Společná konference farmakologických a toxikologických společností

SAVE THE DATE

Datum: **9.–11. 9. 2026**

Místo: **Univerzitní kampus Bohunice, Kamenice 753/5, Brno**

Společná konference farmakologických a toxikologických společností:

73. Česko-slovenské farmakologické dny

31. konference TOXCON

29. Česká konference TDM

25. Česká konference klinické farmakologie